<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776434</url>
  </required_header>
  <id_info>
    <org_study_id>S2020-01</org_study_id>
    <nct_id>NCT04776434</nct_id>
  </id_info>
  <brief_title>SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study</brief_title>
  <acronym>SUCCESS PTA</acronym>
  <official_title>SUCCESS (SelUtion, Safety, effiCaCy, hEalth economicS and promS) PTA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.A. Med Alliance S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.A. Med Alliance S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open label, real-world, prospective, multi-center, single arm, post-market surveillance study&#xD;
      of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, real-world, prospective, multi-center, single arm, post-market surveillance study&#xD;
      of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).&#xD;
&#xD;
      This study will capture data from the use of the SELUTION SLR according to its approved&#xD;
      labelling. Each indication for use will have a specific data sets in addition to generic data&#xD;
      sets that are common across all indications.&#xD;
&#xD;
      Patients will be followed for 5 years post-procedure to obtain safety and efficacy data. A&#xD;
      health economic analysis will be made comparing data between countries within the study and&#xD;
      to published data for existing treatment options. Generic and disease specific Patient&#xD;
      Reported Outcome Measures (PROMs) will be used to measure the impact of the intervention on&#xD;
      the overall health status of patients.&#xD;
&#xD;
      Imaging data collection for patients whose standard of care includes imaging follow-up will&#xD;
      be captured and analysed.&#xD;
&#xD;
      Data will be collected from any subject who receives a CE marked device for treatment of a&#xD;
      peripheral (i.e. non-cardiovascular) vascular lesion.&#xD;
&#xD;
      Data analysis will be stratified by lesion location.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2027</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically Driven Target Lesion Revascularization</measure>
    <time_frame>1 year after treatment</time_frame>
    <description>The primary endpoint will be freedom from Clinically Driven Target Lesion Revascularisation (CD-TLR) at 1-year post-intervention.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>At end of procedure</time_frame>
    <description>Successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below rated burst pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure success</measure>
    <time_frame>At end of procedure</time_frame>
    <description>Device success and residual stenosis ≤50% at the end of the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>At discharge after procedure</time_frame>
    <description>Procedural success without procedural complications (death, major target limb amputation, thrombosis of the target lesion or TLR) prior to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Limb Events (MALE) composite endpoint</measure>
    <time_frame>At discharge after procedure and 1, 6, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Severe limb ischemia leading to an intervention or major vascular amputation (above the ankle).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Cardiac Events Major Cardiac Events</measure>
    <time_frame>At 1, 6, 12, 24, 36,48, 60 months</time_frame>
    <description>MI, Stroke, Cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>At 1, 6, 12, 24, 36, 48, 60 months</time_frame>
    <description>All-cause, cardiac, device related, procedure related</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TLR</measure>
    <time_frame>At 1, 6, 12, 24, 36, 48, 60 months</time_frame>
    <description>Number of Target Lesion Revascularizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TVR</measure>
    <time_frame>At 1, 6, 12, 24, 36, 48, 60 months</time_frame>
    <description>Number of Target Vessel Revascularizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first CD-TLR</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Time to first Clinically Driven Target Lesion Revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target limb revascularization</measure>
    <time_frame>At 1, 6, 12, 24, 36, 48, 60 months</time_frame>
    <description>Number of Target limb revascularizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis at the target site</measure>
    <time_frame>At 1 month</time_frame>
    <description>Number of Thrombosis at the target site</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation</measure>
    <time_frame>up to 60 months</time_frame>
    <description>Number of Amputations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rutherford Classification score</measure>
    <time_frame>At 6, 12, 24, 36, 48, 60 months</time_frame>
    <description>Change in Rutherford Classification score from baseline (Scale from 0 to 6, higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle Brachial Index (ABI)</measure>
    <time_frame>At 6, 12 months only</time_frame>
    <description>Change in ankle brachial index (ABI) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pedal pulse</measure>
    <time_frame>6, 12 months only</time_frame>
    <description>Presence of Pedal pulse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wound status if applicable</measure>
    <time_frame>6, 12 months only</time_frame>
    <description>location, size, infection, status, Wound, Ischemia and Foot Infection (WIfI) classification system score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kawarada Classification score</measure>
    <time_frame>At end of procedure</time_frame>
    <description>Change from baseline to end of procedure to assess change in severity of Pedal Artery Disease</description>
  </secondary_outcome>
  <enrollment type="Anticipated">722</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)</intervention_name>
    <description>This study will capture data from the use of the SELUTION SLR according to its approved labelling.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject age is ≥ 18 years&#xD;
&#xD;
          -  Subject is able and willing to provide informed consent&#xD;
&#xD;
          -  Subject is suitable for treatment with a MedAlliance SELUTION SLR DEB according to the&#xD;
             current Instruction for use.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  In the opinion of the treating investigator the subject has a life expectancy of less&#xD;
             than 12 months&#xD;
&#xD;
          -  In the opinion of the treating investigator the subject is unlikely to comply with the&#xD;
             study follow-up regime&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tamarah Suys</last_name>
    <phone>+41223637890</phone>
    <email>tsuys@medalliance.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Hochsauerland</name>
      <address>
        <city>Arnsberg</city>
        <zip>59759</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Lichtenberg</last_name>
      <email>m.lichtenberg@klinikum-hochsauerland.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 10, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

